NCI Clinical and Translational Exploratory/Developmental Studies (R21)

This grant supports the development of new exploratory research in cancer diagnosis, treatment, imaging, symptom/toxicity, and prevention clinical trials; correlative studies associated with clinical trials; novel cancer therapeutic, symptom/toxicity, and preventive agent development, radiotherapy development activities, and mechanism-driven combinations; innovative preclinical studies, including the use of new clinically-relevant models and imaging technologies, which could lead to first-in-human clinical trials, and therapeutic outcome disparities, including biomarkers or genetic/epigenetic signatures, among diverse racial/ethnic populations, including genetically engineered mouse models, patient-derived xenograft models, organoids, and cell lines.

Funding: $275,000 total 

Duration: 2 years 

Research Autority due date: 10 days prior to submission

LOI (encouraged) due dates:  8.9.19, 20.1.20,19.5.20, 20.9.20, 19.1.21, 21.5.21, 20.9.21, 22.1.22, 21.5.22

Full proposal due dates: 8.10.19, 20.2.20,19.6.20, 20.10.20, 19.2.21, 21.6.21, 20.10.21, 22.2.22, 21.6.22